Health insurance provider Elevance Health (NYSE: ELV) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $50.44 billion. Its non-GAAP profit of $6.99 per share was 48.9% above analysts’ consensus estimates.

Is now the time to buy ELV? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Elevance Health’s third quarter results were defined by stronger-than-expected performance in government and individual health lines, particularly Medicaid, Medicare Advantage, and Individual ACA. Management pointed to focused execution and recent Medicaid rate actions as key contributors, with CEO Gail Boudreaux highlighting, “These results reflect focused execution across the enterprise.” Operational improvements in Carelon and disciplined cost management also supported the company’s outperformance relative to Wall Street expectations.

Looking forward, management raised its full-year adjusted earnings outlook, citing confidence in continued margin improvement across health benefits and the growing contribution of Carelon’s value-based solutions. CFO Mark Kaye emphasized, “We remain confident in delivering at least 12% adjusted EPS growth in 2027 from this higher baseline.” The company’s strategy centers on integrating medical and pharmacy offerings, expanding Carelon’s external reach, and advancing cost management through technology and clinical oversight.

Key insights from management’s remarks

Management attributed the quarter’s results to disciplined cost controls, improved Medicaid rate alignment, and expanded adoption of Carelon’s integrated solutions, which together drove better operating performance in several core business lines.

• Medicaid margin stabilization: Recent rate increases and targeted clinical management actions helped stabilize Medicaid margins and set up the segment for improvement in 2027. Management noted ongoing efforts to align rates with cost trends and proactively address behavioral health utilization.

• CarelonRx and value-based care: Strong operating performance in CarelonRx was driven by integration of medical and pharmacy benefits, with members in integrated plans experiencing fewer emergency room visits and significant per-member-per-month savings. The introduction of specialized programs, like the Oncology Center of Excellence, has enhanced patient outcomes and operational efficiency.

• Commercial segment pricing discipline: The Commercial business benefited from prudent pricing and a focus on affordable, integrated solutions. Management underscored the importance of alternative funding models and highlighted wins in the large employer space, including clients returning to Anthem offerings after brief absences.

• Medicare Advantage repositioning: Deliberate changes in product and market focus for Medicare Advantage led to improved quality mix and operating margins. Management is prioritizing HMO plans and dual-eligible members, aiming to further increase the share of members in higher-rated plans.

• AI and analytics in cost management: The company is increasingly leveraging AI-enabled analytics to identify abnormal utilization patterns, particularly in behavioral health and payment integrity. These efforts have contributed to early identification of cost drivers and expedited corrective actions, with notable impact on claims management and fraud detection.

Drivers of future performance

Elevance Health’s full-year outlook is shaped by margin recovery in Medicaid, continued Carelon expansion, and operational efficiency initiatives.

• Medicaid margin improvement: Management expects Medicaid margins to begin recovering in 2027 as state rates better reflect underlying cost trends and targeted interventions in behavioral health and care management take hold. However, the pace of recovery depends on how quickly states incorporate higher costs into rate-setting and the impact of new work requirements.

• Carelon external growth and integration: The company is scaling Carelon’s offerings beyond affiliated health plans, focusing on external client wins in behavioral health, pharmacy, and post-acute care. Leadership highlighted high retention rates and a robust sales pipeline, supporting expectations for Carelon to become a larger contributor to enterprise earnings.

• Commercial and ACA market discipline: In the Commercial segment, pricing for stability amid elevated cost trends is a priority, while ACA market performance benefits from product mix shifts and disciplined rate filings. Management cautions that the risk pool in ACA will take more than one cycle to normalize as enhanced subsidies expire.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will watch (1) the pace of Medicaid margin recovery as rate adjustments and care management initiatives progress, (2) Carelon’s success in expanding its external client base and executing on integrated value-based care, and (3) the commercial segment’s ability to maintain pricing discipline amid cost trend pressures. Developments in regulatory policy, particularly around work requirements and IDR, will also be key for future performance.

Elevance Health currently trades at $436.75, in line with $440.18 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.